DBV Technologies Stock to Reverse Split on Friday, November 29th (NASDAQ:DBVT)

DBV Technologies S.A. (NASDAQ:DBVT)’s stock is set to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 28th.

DBV Technologies Price Performance

DBV Technologies stock opened at $0.63 on Wednesday. DBV Technologies has a one year low of $0.50 and a one year high of $2.14. The business’s fifty day moving average is $0.74 and its 200 day moving average is $0.90. The stock has a market capitalization of $61.18 million, a PE ratio of -0.75 and a beta of 0.66.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a research note on Tuesday, September 24th. StockNews.com started coverage on shares of DBV Technologies in a research report on Wednesday, November 6th. They issued a “hold” rating for the company. Finally, HC Wainwright increased their price target on DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, October 24th.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. raised its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the period. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.